160132-86-5

Basic information

• Product Name: Piperidine, 4-(4-nitrophenyl)-1-(trifluoroacetyl)-
• Synonyms: 1-trifluoroacetyl-4-(4-nitrophenyl)piperidine;Piperidine,4-(4-nitrophenyl)-1-(trifluoroacetyl);2,2,2-trifluoro-1-[4-(4-nitro-phenyl)-piperidin-1-yl]-ethanone;4-(1-trifluoroacetyl-4-piperidinyl)-nitrobenzene;4-(4-nitrophenyl)-1-trifluoroacetylpiperidine
• CAS NO: 160132-86-5
• Molecular Formula: C13H13F3N2O3
• Molecular Weight: 302.253
• Mol File: 160132-86-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Piperidine, 4-(4-nitrophenyl)-1-(trifluoroacetyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Piperidine, 4-(4-nitrophenyl)-1-(trifluoroacetyl)-(160132-86-5)
• EPA Substance Registry System: Piperidine, 4-(4-nitrophenyl)-1-(trifluoroacetyl)-(160132-86-5)

Safety Data

• Hazardous Substances Data: 160132-86-5(Hazardous Substances Data)

Upstream product

• 157133-89-6 2,2,2-trifluoro-1-(4-phenyl-1-piperidinyl)-1-ethanone 
• 26905-03-3 4-(4-Nitrophenyl)piperidine 
• 407-25-0 trifluoroacetic anhydride 

Downstream Products

• 959755-81-8 1-(2,2,2-trifluoroethyl)-4-(4-nitrophenyl)piperidine 
• 957345-79-8 N-{4-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]phenyl}formamide 
• 957345-82-3 4-[1-(2 2,2-trifluoroethyl)piperidin-4-yl]phenylamine 
• 883194-93-2 4-(4-nitro-phenyl)-piperidine hydrochloride 

Relevant articles and documents

IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula ( I ) represented by the following:The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.

PI3 KINASES

The invention relates to the novel compounds of formula (1), which, due to their pharmaceutical effect as PI3 kinase modulators, are suitable for use in the therapy and treatment of inflammatory or allergic diseases. Examples of these diseases are inflammatory and allergic respiratory diseases, inflammatory diseases of the gastro-intestinal system and of the locomotor apparatus, inflammatory and allergic skin diseases, inflammatory ophthalmic diseases, diseases of the nasal mucosa, inflammatory or allergic autoimmune reactive conditions, or renal inflammations.

Cyclic urea derivatives, pharmaceutical compositions containing these compounds and processes for preparing them

The invention relates to cyclic urea derivatives of general formula I STR1 wherein Ra, Rb, X and Y are defined as in claim 1, the tautomers, stereoisomers and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable pharmacological properties, preferably aggregation inhibiting effects, and to drugs containing the compounds and processes for preparing them.